Coffee and Compatibility is a monthly ASHI Podcast discussing current topics and expert opinions relating to transplantation, histocompatibility and immunogenetics. The podcast will include personal interviews from the American Society of Histocompatibility and Immunogenetics (ASHI) members, ASHI leadership, intriguing ASHI personalities, and discussions of current trends in transplantation.
As the field of cellular therapies evolves, allogeneic therapies are quickly growing and becoming very attractive due to the plethora of available cell sources and the flexibility of building off-the-shelf cell banks. However, histocompatibility between the cell donors and therapy recipients plays an important factor. In particular, the role of HLA matching is unclear in impacting the success of multiple cellular therapies, when to account for it, when to avoid and when to take particular considerations. This session will touch on some recent advances in allogeneic cellular therapies and discuss some important histocompatibility issues cellular therapy developers and testing labs are facing through the experiences of some esteemed experts in the field. Session developed by Ketty Gendzekhadze, Abeer Madbouly and Jerry Morris, program planning committee.
Speaker: Colleen Delaney, MD, MSc – Deverra Therapeutics
Speaker: Ketty Gendzekhadze, MSc, PhD, F(ACHI) – City of Hope
Speaker: Heather Stefanski, MD PhD – NMDP
Moderator: Abeer Madbouly, PhD – NMDP
Moderator: Melody Zhang, MD, A(ACHI) – Stanford University
As the field of cellular therapies evolves, allogeneic therapies are quickly growing and becoming very attractive due to the plethora of available cell sources and the flexibility of building off-the-shelf cell banks. However, histocompatibility between the cell donors and therapy recipients plays an important factor. In particular, the role of HLA matching is unclear in impacting the success of multiple cellular therapies, when to account for it, when to avoid and when to take particular considerations. This session will touch on some recent advances in allogeneic cellular therapies and discuss some important histocompatibility issues cellular therapy developers and testing labs are facing through the experiences of some esteemed experts in the field. Session developed by Ketty Gendzekhadze, Abeer Madbouly and Jerry Morris, program planning committee.
Xenotransplantation, long regarded as the perpetual future of organ transplantation, has recently undergone a notable resurgence. In the past five years, we have seen the clinical implementation of heart and kidney xenografts in living human recipients. If successful, this approach will not only alleviate the critical shortage of transplantable organs but also present new challenges and opportunities for the transplantation and histocompatibility communities. Key among these challenges is determining how to select and effectively match patients with genetically engineered pig donors. In this session, we will examine the clinical need for xenotransplantation, the complexities and challenges of using pigs as organ donors, current strategies for assessing histocompatibility in the context of xenotransplantation, and future directions for xenocompatibility testing. Session developed by Anne Halpin, Luis Hidalgo, James Lan and Rob Liwski, program planning committee.